Advent International has outbid KKR in a private equity bidding war for Spectris after the UK industrial group accepted its ...

(Reuters) -British scientific instruments maker Spectris has agreed to private equity firm Advent's sweetened takeover offer ...

Advent International said it increased its takeover bid for precision-measurement company Spectris to 4.2 billion pounds ($5.55 billion).

Precision instrument maker Spectris has agreed to be bought by Advent International after it trumped an offer from US ...

British scientific instruments maker Spectris has agreed to private equity firm Advent's sweetened takeover bid valued at 4.8 billion pounds ($6.38 billion), including debt, the companies said on ...

Advent’s increased offer represents a 2.5 percent increase to the KKR offer. This means the shareholders will receive an additional £1.00 per share, amounting to a total increase of £101.5 million ...

The firm is acting for the Just Group in its £2.4 billion sale, a month after it helped conclude the sale of Spectris to a ...

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease ...

Cognito Therapeutics today announced the presentation of new findings from a study of its non-invasive Spectris neuromodulation system.

Spectris' Earnings Growth And 10% ROE To begin with, Spectris seems to have a respectable ROE. Even when compared to the industry average of 10% the company's ROE looks quite decent.

Cognito’s lead product, Spectris, employs a proprietary non-invasive method designed to evoke increased gamma frequency brain activity using auditory and visual neuromodulation to slow the rate ...

Spectris™ is currently being evaluated in HOPE, a pivotal, randomized, sham-controlled trial enrolling 670 patients with mild-to-moderate Alzheimer’s disease.